Targeting ALK in inflammatory myofibroblastic tumours

Affiliations

¹ Sarcoma Program, Division of Medical Oncology, University of Colorado Anschutz Medical Campus, University of Colorado Cancer Center, Aurora, CO, 80045, USA.
² Thoracic Oncology Program, Division of Medical Oncology, University of Colorado Anschutz Medical Campus, University of Colorado Cancer Center, Aurora, CO, 80045, USA. Electronic address: ross.camidge@ucdenver.edu.

Comment

Victor M Villalobos et al. Lancet Respir Med. 2018 Jun.

. 2018 Jun;6(6):405-407.

doi: 10.1016/S2213-2600(18)30147-4. Epub 2018 Apr 15.

¹ Sarcoma Program, Division of Medical Oncology, University of Colorado Anschutz Medical Campus, University of Colorado Cancer Center, Aurora, CO, 80045, USA.
² Thoracic Oncology Program, Division of Medical Oncology, University of Colorado Anschutz Medical Campus, University of Colorado Cancer Center, Aurora, CO, 80045, USA. Electronic address: ross.camidge@ucdenver.edu.

No abstract available

Comment on

Crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumours with and without anaplastic lymphoma kinase gene alterations (European Organisation for Research and Treatment of Cancer 90101 CREATE): a multicentre, single-drug, prospective, non-randomised phase 2 trial.
Schöffski P, Sufliarsky J, Gelderblom H, Blay JY, Strauss SJ, Stacchiotti S, Rutkowski P, Lindner LH, Leahy MG, Italiano A, Isambert N, Debiec-Rychter M, Sciot R, Van Cann T, Marréaud S, Nzokirantevye A, Collette S, Wozniak A. Schöffski P, et al. Lancet Respir Med. 2018 Jun;6(6):431-441. doi: 10.1016/S2213-2600(18)30116-4. Epub 2018 Apr 15. Lancet Respir Med. 2018. PMID: 29669701 Clinical Trial.